ProCE Banner Activity

Therapeutic Landscape for Patients With MF and JAK Inhibitor Failure


Download this slideset from a live symposium at ASCO 2023 to review expert perspectives on approved and investigational approaches to the treatment of patients with myelofibrosis and prior JAK inhibitor therapy.

Released: June 02, 2023



John Mascarenhas

John Mascarenhas, MD

Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute 
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie, Inc., CTI BioPharma, GSK, and Incyte Corporation.

AbbVie, Inc.

CTI BioPharma


Incyte Corporation